About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2012 (2012), Article ID 479712, 11 pages
http://dx.doi.org/10.1155/2012/479712
Research Article

Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene

1Department of Orthopaedics, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
2Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
3Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA

Received 23 August 2011; Accepted 20 February 2012

Academic Editor: Quincy Chu

Copyright © 2012 Patrick J. Messerschmitt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Surveillance and End Results (SEER) Program, SEER Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973–2005 varying)—Linked to County Attributes—Total U.S., 1969–2005, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2008.
  2. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, pp. 776–790, 2002.
  3. A. M. Davis, R. S. Bell, and P. J. Goodwin, “Prognostic factors in osteosarcoma: a critical review,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 423–431, 1994. View at Scopus
  4. P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty, “Osteosarcoma,” Journal of the American Academy of Orthopaedic Surgeons, vol. 17, no. 8, pp. 515–527, 2009. View at Scopus
  5. P. A. Meyers, C. L. Schwartz, M. Krailo et al., “Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2004–2011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Chou, E. S. Kleinerman, M. D. Krailo et al., “Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group,” Cancer, vol. 115, no. 22, pp. 5339–5348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. A. Meyers, C. L. Schwartz, M. D. Krailo et al., “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the children's oncology group,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 633–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Kaap, I. Quentin, D. Tamiru, M. Shaheen, K. Eger, and H. J. Steinfelder, “Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds,” Biochemical Pharmacology, vol. 65, no. 4, pp. 603–610, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Kim, J. H. Kim, G. E. Lee, J. E. Lee, and I. K. Chung, “Potent inhibition of human telomerase by nitrostyrene derivatives,” Molecular Pharmacology, vol. 63, no. 5, pp. 1117–1124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Mohan, N. Rastogi, I. N. N. Namboothiri, S. M. Mobin, and D. Panda, “Synthesis and evaluation of α-hydroxymethylated conjugated nitroalkenes for their anticancer activity: inhibition of cell proliferation by targeting microtubules,” Bioorganic & Medicinal Chemistry, vol. 14, no. 23, pp. 8073–8085, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Y. Wang, P. W. Hsieh, Y. C. Wu, and C. C. Wu, “Synthesis and pharmacological evaluation of novel β-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity,” Biochemical Pharmacology, vol. 74, no. 4, pp. 601–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Y. Wang, Y. C. Wu, and C. C. Wu, “Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-β-nitrostyrene, a novel tyrosine kinase inhibitor,” Molecular Pharmacology, vol. 70, no. 4, pp. 1380–1389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Levitzki and E. Mishani, “Tyrphostins and other tyrosine kinase inhibitors,” Annual Review of Biochemistry, vol. 75, pp. 93–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Messerschmitt, A. N. Rettew, R. E. Brookover, R. M. Garcia, P. J. Getty, and E. M. Greenfield, “Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2168–2175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. P. M. Hughes, D. G. Thomas, T. J. Giordano, K. T. McDonagh, and L. H. Baker, “Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition,” Pediatric Blood and Cancer, vol. 46, no. 5, pp. 614–623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Coopman and S. C. Mueller, “The Syk tyrosine kinase: a new negative regulator in tumor growth and progression,” Cancer Letters, vol. 241, no. 2, pp. 159–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Rezzonico, A. Schmid-Alliana, G. Romey et al., “Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells,” Journal of Bone and Mineral Research, vol. 17, no. 5, pp. 869–878, 2002. View at Scopus
  18. S. Yanagi, R. Inatome, T. Takano, and H. Yamamura, “Syk expression and novel function in a wide variety of tissues,” Biochemical and Biophysical Research Communications, vol. 288, no. 3, pp. 495–498, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Craxton, A. Jiang, T. Kurosaki, and E. A. Clark, “Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30644–30650, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. A. Stewart and J. A. Pietenpol, “Syk: a new player in the field of breast cancer,” Breast Cancer Research, vol. 3, no. 1, pp. 5–7, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Bradshaw, “The Src, Syk, and Tec family kinases: distinct types of molecular switches,” Cellular Signalling, vol. 22, no. 8, pp. 1175–1184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Turner, E. Schweighoffer, F. Colucci, J. P. Di Santo, and V. L. Tybulewicz, “Tyrosine kinase SYK: essential functions for immunoreceptor signalling,” Immunology Today, vol. 21, no. 3, pp. 148–154, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes, “The role of Src in solid and hematologic malignancies: development of new-generation src inhibitors,” Cancer, vol. 107, no. 8, pp. 1918–1929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb, “Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo,” Clinical Cancer Research, vol. 15, no. 10, pp. 3416–3422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. C. Shor, E. A. Keschman, F. Y. Lee et al., “Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival,” Cancer Research, vol. 67, no. 6, pp. 2800–2808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. L. Worth, S. F. Jia, Z. Zhou, L. Chen, and E. S. Kleinerman, “Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases,” Clinical Cancer Research, vol. 6, no. 9, pp. 3713–3718, 2000. View at Scopus
  27. H. H. Luu, Q. Kang, K. P. Jong et al., “An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis,” Clinical and Experimental Metastasis, vol. 22, no. 4, pp. 319–329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Duan, S. F. Jia, Z. Zhou, R. R. Langley, M. F. Bolontrade, and E. S. Kleinerman, “Association of αvβ3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells,” Clinical and Experimental Metastasis, vol. 21, no. 8, pp. 747–753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. F. Jia, L. L. Worth, and E. S. Kleinerman, “A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies,” Clinical and Experimental Metastasis, vol. 17, no. 6, pp. 501–506, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. Blake, M. A. Broome, X. Liu et al., “SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling,” Molecular and Cellular Biology, vol. 20, no. 23, pp. 9018–9027, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Y. Q. Lai, P. J. Cox, R. Patel et al., “Potent small molecule inhibitors of spleen tyrosine kinase (Syk),” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3111–3114, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Hisamichi, R. Naito, A. Toyoshima et al., “Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives,” Bioorganic & Medicinal Chemistry, vol. 13, no. 16, pp. 4936–4951, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Yamamoto, K. Takeshita, M. Shichijo et al., “The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 1174–1181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Betapudi, L. S. Licate, and T. T. Egelhoff, “Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration,” Cancer Research, vol. 66, no. 9, pp. 4725–4733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. L. Edin, A. K. Howe, and R. L. Juliano, “Inhibition of PKA blocks fibroblast migration in response to growth factors,” Experimental Cell Research, vol. 270, no. 2, pp. 214–222, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. J. C. Dai, P. He, X. Chen, and E. M. Greenfield, “TNFα and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics,” Bone, vol. 38, no. 4, pp. 509–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein kinase inhibitors: a further update,” Biochemical Journal, vol. 408, no. 3, pp. 297–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. N. Rettew, P. J. Getty, and E. M. Greenfield, “Novel receptor tyrosine kinases in osteosarcoma identified by phosphoproteomic and functional genomic screening,” in Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, April 2010.
  39. N. Milhazes, R. Calheiros, M. P. M. Marques et al., “β-Nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study,” Bioorganic & Medicinal Chemistry, vol. 14, no. 12, pp. 4078–4088, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. K. Pettit, G. R. Pettit, E. Hamel et al., “E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes,” Bioorganic & Medicinal Chemistry, vol. 17, no. 18, pp. 6606–6612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. M. McNamara, S. M. Cloonan, A. J. S. Knox et al., “Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents,” Bioorganic & Medicinal Chemistry, vol. 19, no. 3, pp. 1328–1348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. H. Walsh, A. Cheng, and R. E. Honkanen, “Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A,” FEBS Letters, vol. 416, no. 3, pp. 230–234, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. J. M. Werner, K. Eger, and H. Jürgen Steinfelder, “Comparison of the rapid pro-apoptotic effect of trans-β-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells,” Apoptosis, vol. 12, no. 1, pp. 235–246, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Deng, T. Ito, B. Carr, M. Mumby, and W. S. May Jr., “Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A,” Journal of Biological Chemistry, vol. 273, no. 51, pp. 34157–34163, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. N. W. Kim, M. A. Piatyszek, K. R. Prowse et al., “Specific association of human telomerase activity with immortal cells and cancer,” Science, vol. 266, no. 5193, pp. 2011–2015, 1994. View at Scopus